Washington University School Main Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Picus, Joel
NCT02643667: Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

Completed
2
27
US
Ibrutinib, Radical prostatectomy
Washington University School of Medicine, Pharmacyclics LLC.
Prostate Cancer
04/23
04/23
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
KEYNOTE F73, NCT05369000: Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Active, not recruiting
1/2
180
Europe, US
LAVA-1207, LAVA-1207 plus Pembrolizumab
Lava Therapeutics, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
04/27
04/27
CABIOS, NCT04477512: Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer ( Trial)

Active, not recruiting
1
18
US
Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
Washington University School of Medicine, Bristol-Myers Squibb, Exelixis
Metastatic Hormone Refractory Prostate Cancer
09/21
09/25
MK-6482-030, NCT06234605: A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Recruiting
1
80
US
HC-7366, Belzutifan, WELIREG™, MK-6482
HiberCell, Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
11/26
11/27
NCT06529822: Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Not yet recruiting
1
16
US
Synthetic long peptide personalized cancer vaccine, PCV, Poly ICLC, Hiltonol, Signatera assay
Washington University School of Medicine, Natera, Inc.
Muscle-Invasive Bladder Carcinoma
09/28
08/33
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
09/25
09/25
Reilly, Abigail
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
09/25
09/25

Download Options